Partnerships & Mergers

The companies will work together to generate pharmacological and bioanalytical data needed to advance NB4168 toward clinical development.

Both programmes will combine SOPHiA GENETICS’ decentralised clinical trial assay capabilities with AstraZeneca’s oncology therapies.

SMT’s adoption of Teamcenter is intended to improve visibility into product development activities while helping the company manage the documentation and controls required in the highly regulated medical device industry.

The partnership will unlock KSh10.4 billion (US$80 million) over the next five years to accelerate implementation of Kenya’s Every Woman Every Newborn Everywhere (EWENE) Acceleration Plan and support the country’s 90-90-80-80 maternal and newborn health targets.

IMPACT Therapeutics received approval from China’s National Medical Products Administration (NMPA) in January 2025 for senaparib as a first-line maintenance therapy for adults with advanced ovarian, fallopian tube, or primary peritoneal cancer.

The partnership combines Budenheim’s manufacturing expertise with Brenntag’s biopharma services and distribution network.

Under the agreements, MSD will work with Aspen Pharmacare in South Africa, Quality Chemicals Industries Limited (QCIL) in Uganda and Universal Corporation Limited (UCL) in Kenya.

Under the agreement, CORE Biomedicine will evaluate and develop the licensed programmes with the aim of creating targeted treatments for a wider range of cancer patients.

The partnership combines Africa CDC’s continental leadership in health security with PSI’s experience in working with governments, communities and partners to design and scale people-centred healthcare solutions.

Under the proposed agreement, argenx will pay US$77 per share in cash to acquire all outstanding shares of Forte Biosciences.